- Home
- SPH vs XNCR Comparison
SPH vs XNCR Comparison
Compare SPH & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPH | XNCR |
|---|---|---|
| Founded | 1945 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SPH | XNCR |
|---|---|---|
| Price | $18.70 | $15.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $22.78 |
| AVG Volume (30 Days) | 158.1K | ★ 772.9K |
| Earning Date | 02-05-2026 | 11-05-2025 |
| Dividend Yield | ★ 6.97% | N/A |
| EPS Growth | ★ 42.10 | N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $1,432,518,000.00 | $150,132,000.00 |
| Revenue This Year | $2.06 | $18.81 |
| Revenue Next Year | $1.64 | N/A |
| P/E Ratio | $11.51 | ★ N/A |
| Revenue Growth | 7.94 | ★ 38.16 |
| 52 Week Low | $16.92 | $6.92 |
| 52 Week High | $22.24 | $24.66 |
Technical Indicators
Market Signals| Indicator | SPH | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 41.79 |
| Support Level | $18.54 | $14.97 |
| Resistance Level | $18.90 | $16.17 |
| Average True Range (ATR) | 0.32 | 0.67 |
| MACD | -0.03 | -0.27 |
| Stochastic Oscillator | 36.67 | 4.04 |
Price Performance
Historical ComparisonAbout SPH Suburban Propane Partners L.P.
Suburban Propane Partners LP distributes propane, fuel oil, and other refined fuels to customers in the East Coast and West Coast regions of the United States. Other operations include natural gas and electricity marketing in the deregulated New York and Pennsylvania markets. The company operates in three segments: Propane; Fuel Oil and Refined Fuels; and Natural Gas and Electricity. It generates maximum revenue from Propane segment.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.